82 related articles for article (PubMed ID: 21950196)
1. Effectiveness of melatonin in tardive dyskinesia.
Castro F; Carrizo E; Prieto de Rincón D; Rincón CA; Asián T; Medina-Leendertz S; Bonilla E
Invest Clin; 2011 Sep; 52(3):252-60. PubMed ID: 21950196
[TBL] [Abstract][Full Text] [Related]
2. A double-blind placebo-controlled study of vitamin E treatment of tardive dyskinesia.
Lohr JB; Caligiuri MP
J Clin Psychiatry; 1996 Apr; 57(4):167-73. PubMed ID: 8601552
[TBL] [Abstract][Full Text] [Related]
3. Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study.
Bai YM; Yu SC; Lin CC
J Clin Psychiatry; 2003 Nov; 64(11):1342-8. PubMed ID: 14658949
[TBL] [Abstract][Full Text] [Related]
4. The effect of vitamin E treatment on tardive dyskinesia and blood superoxide dismutase: a double-blind placebo-controlled trial.
Zhang XY; Zhou DF; Cao LY; Xu CQ; Chen DC; Wu GY
J Clin Psychopharmacol; 2004 Feb; 24(1):83-6. PubMed ID: 14709952
[TBL] [Abstract][Full Text] [Related]
5. Melatonin treatment for tardive dyskinesia: a double-blind, placebo-controlled, crossover study.
Shamir E; Barak Y; Shalman I; Laudon M; Zisapel N; Tarrasch R; Elizur A; Weizman R
Arch Gen Psychiatry; 2001 Nov; 58(11):1049-52. PubMed ID: 11695951
[TBL] [Abstract][Full Text] [Related]
6. No difference in the effect of biperiden and amantadine on parkinsonian- and tardive dyskinesia-type involuntary movements: a double-blind crossover, placebo-controlled study in medicated chronic schizophrenic patients.
Silver H; Geraisy N; Schwartz M
J Clin Psychiatry; 1995 Apr; 56(4):167-70. PubMed ID: 7713856
[TBL] [Abstract][Full Text] [Related]
7. Bilateral deep brain stimulation of the globus pallidus to treat tardive dyskinesia.
Damier P; Thobois S; Witjas T; Cuny E; Derost P; Raoul S; Mertens P; Peragut JC; Lemaire JJ; Burbaud P; Nguyen JM; Llorca PM; Rascol O;
Arch Gen Psychiatry; 2007 Feb; 64(2):170-6. PubMed ID: 17283284
[TBL] [Abstract][Full Text] [Related]
8. Vitamin B6 in treatment of tardive dyskinesia: a preliminary case series study.
Lerner V; Kaptsan A; Miodownik C; Kotler M
Clin Neuropharmacol; 1999; 22(4):241-3. PubMed ID: 10442256
[TBL] [Abstract][Full Text] [Related]
9. Is melatonin treatment effective for tardive dyskinesia?
Shamir E; Barak Y; Plopsky I; Zisapel N; Elizur A; Weizman A
J Clin Psychiatry; 2000 Aug; 61(8):556-8. PubMed ID: 10982197
[TBL] [Abstract][Full Text] [Related]
10. Vitamin E in the treatment of tardive dyskinesia.
Akhtar S; Jajor TR; Kumar S
J Postgrad Med; 1993; 39(3):124-6. PubMed ID: 7914238
[TBL] [Abstract][Full Text] [Related]
11. Buspirone in the treatment of tardive dyskinesia.
Moss LE; Neppe VM; Drevets WC
J Clin Psychopharmacol; 1993 Jun; 13(3):204-9. PubMed ID: 8102622
[TBL] [Abstract][Full Text] [Related]
12. Botulinum toxin in the treatment of orofacial tardive dyskinesia: a single blind study.
Slotema CW; van Harten PN; Bruggeman R; Hoek HW
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):507-9. PubMed ID: 18022743
[TBL] [Abstract][Full Text] [Related]
13. Effects of zonisamide on tardive dyskinesia: a preliminary open-label trial.
Iwata Y; Irie S; Uchida H; Suzuki T; Watanabe K; Iwashita S; Mimura M
J Neurol Sci; 2012 Apr; 315(1-2):137-40. PubMed ID: 22285275
[TBL] [Abstract][Full Text] [Related]
14. Double-blind carbidopa/levodopa and placebo study in tardive dyskinesia.
Simpson GM; Yadalam KG; Stephanos MJ
J Clin Psychopharmacol; 1988 Aug; 8(4 Suppl):49S-51S. PubMed ID: 2906069
[TBL] [Abstract][Full Text] [Related]
15. Extract of Ginkgo biloba treatment for tardive dyskinesia in schizophrenia: a randomized, double-blind, placebo-controlled trial.
Zhang WF; Tan YL; Zhang XY; Chan RC; Wu HR; Zhou DF
J Clin Psychiatry; 2011 May; 72(5):615-21. PubMed ID: 20868638
[TBL] [Abstract][Full Text] [Related]
16. Incidence of extrapyramidal symptoms and tardive dyskinesia in schizophrenia: thirty-six-month results from the European schizophrenia outpatient health outcomes study.
Novick D; Haro JM; Bertsch J; Haddad PM
J Clin Psychopharmacol; 2010 Oct; 30(5):531-40. PubMed ID: 20814320
[TBL] [Abstract][Full Text] [Related]
17. [Vitamin B6 add-on therapy in treatment of schizophrenic patients with psychotic symptoms and movement disorders].
Miodownik C; Cohen H; Kotler M; Lerner V
Harefuah; 2003 Sep; 142(8-9):592-6, 647. PubMed ID: 14518160
[TBL] [Abstract][Full Text] [Related]
18. NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double-blind, placebo-controlled study.
O'Brien CF; Jimenez R; Hauser RA; Factor SA; Burke J; Mandri D; Castro-Gayol JC
Mov Disord; 2015 Oct; 30(12):1681-7. PubMed ID: 26346941
[TBL] [Abstract][Full Text] [Related]
19. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients.
Chouinard G; Jones B; Remington G; Bloom D; Addington D; MacEwan GW; Labelle A; Beauclair L; Arnott W
J Clin Psychopharmacol; 1993 Feb; 13(1):25-40. PubMed ID: 7683702
[TBL] [Abstract][Full Text] [Related]
20. The use of clonidine in the treatment of neuroleptic-induced tardive dyskinesia.
Browne J; Silver H; Martin R; Hart R; Mergener M; Williams P
J Clin Psychopharmacol; 1986 Apr; 6(2):88-92. PubMed ID: 2871058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
